Literature DB >> 31559852

Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease.

Swetha R Palli1, Ami R Buikema2, Mary DuCharme2, Monica Frazer2, Shuchita Kaila1, Timothy Juday1.   

Abstract

Aim: To compare health plan-paid costs, exacerbations and pneumonia outcomes for patients with chronic obstructive pulmonary disease (COPD) initiating combination tiotropium olodaterol (TIO + OLO) versus triple therapy (TT: long-acting muscarinic antagonist + long-acting β2 agonists + inhaled corticosteroid). Patients & methods: COPD patients initiating TIO + OLO or TT between 1 January 2014 and 30 June 2016 were identified from a managed care Medicare database and balanced for baseline characteristics using inverse probability of treatment weighting before assessment of outcomes.
Results: Annual COPD-related and all-cause costs were US$4118 (35%) and US$5384 (23%) lower for TIO + OLO versus TT (both p ≤ 0.001). TIO + OLO patients had nearly half the severe exacerbations (8.3 vs 15.5%; p = 0.014) and pneumonia was also less common (18.9 vs 30.9%; p < 0.001).
Conclusion: TIO + OLO was associated with improved economic and COPD health outcomes versus TT.

Entities:  

Keywords:  COPD exacerbation; healthcare costs; healthcare resource use; pneumonia; tiotropium olodaterol; triple therapy

Mesh:

Substances:

Year:  2019        PMID: 31559852     DOI: 10.2217/cer-2019-0101

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  2 in total

Review 1.  Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD.

Authors:  Surya P Bhatt; Cori Blauer-Peterson; Erin K Buysman; Lindsay G S Bengtson; Swetha R Paine Iii
Journal:  Chronic Obstr Pulm Dis       Date:  2022-04-29

2.  Costs and Clinical Consequences of Compliance with COPD GOLD Recommendations or National Guidelines Compared with Current Clinical Practice in Belgium, Germany, Sweden, and the United States.

Authors:  Sanjay Sethi; Antony Wright; Elisabeth Sophia Hartgers-Gubbels; Marlene Hechtner; Brendan Clark; Ciara Wright; Sue Langham; Roland Buhl
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.